134 related articles for article (PubMed ID: 31861433)
1. RECIL versus Lugano for Treatment Response Assessment in FDG-Avid Non-Hodgkin Lymphomas: A Head-to-Head Comparison in 54 Patients.
Berzaczy D; Haug A; Staber PB; Raderer M; Kiesewetter B; Jaeger U; Kornauth C; Simonitsch-Klupp I; Mayerhoefer ME
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31861433
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials.
Kostakoglu L; Martelli M; Sehn LH; Davies A; Trněný M; Herold M; Vitolo U; Hiddemann W; Trotman J; Knapp A; Mattiello F; Nielsen TG; Sahin D; Sellam G; Ward C; Younes A
EJHaem; 2023 Nov; 4(4):1042-1051. PubMed ID: 38024624
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Lugano Criteria Versus RECIL and PERCIST as Prognostic Factors in Diffuse Large B-Cell Lymphoma.
Tang P; Cui F; Jiang C; Zhou Y; Su M; Tian R
Clin Nucl Med; 2024 Apr; 49(4):308-311. PubMed ID: 38271234
[TBL] [Abstract][Full Text] [Related]
4. A retrospective head-to-head comparison of the Lugano classification and PERCIST for FDG-PET/CT response assessment in diffuse large B-cell lymphoma.
Nielsen NB; Gerke O; Nielsen AL; Juul-Jensen K; Larsen TS; Møller MB; Hildebrandt MG
Clin Physiol Funct Imaging; 2024 Jan; 44(1):70-78. PubMed ID: 37501554
[TBL] [Abstract][Full Text] [Related]
5. PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up.
Karls S; Shah H; Jacene H
Semin Nucl Med; 2018 Jan; 48(1):37-49. PubMed ID: 29195616
[TBL] [Abstract][Full Text] [Related]
6. Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteria.
Winkelmann M; Blumenberg V; Rejeski K; Bücklein VL; Ingenerf M; Unterrainer M; Schmidt C; Dekorsy FJ; Bartenstein P; Ricke J; von Bergwelt-Baildon M; Subklewe M; Kunz WG
Cancer Imaging; 2023 May; 23(1):44. PubMed ID: 37189191
[TBL] [Abstract][Full Text] [Related]
7.
Tamayo P; Martín A; Díaz L; Cabrero M; García R; García-Talavera P; Caballero D
Rev Esp Med Nucl Imagen Mol; 2017; 36(5):312-321. PubMed ID: 28483374
[TBL] [Abstract][Full Text] [Related]
8. Different predictive values of interim
Kim J; Lee JO; Paik JH; Lee WW; Kim SE; Song YS
Ann Nucl Med; 2017 Jan; 31(1):1-11. PubMed ID: 27627889
[TBL] [Abstract][Full Text] [Related]
9. Interobserver Agreement of Interim and End-of-Treatment
Burggraaff CN; Cornelisse AC; Hoekstra OS; Lugtenburg PJ; De Keizer B; Arens AIJ; Celik F; Huijbregts JE; De Vet HCW; Zijlstra JM;
J Nucl Med; 2018 Dec; 59(12):1831-1836. PubMed ID: 29728515
[TBL] [Abstract][Full Text] [Related]
10. [Update on the use of FDG-PET/CT in malignant lymphoma].
Terauchi T
Rinsho Ketsueki; 2016; 57(10):2008-2012. PubMed ID: 27795508
[TBL] [Abstract][Full Text] [Related]
11. A comparison of clinical staging using the Lugano versus Ann Arbor classifications in Japanese patients with Hodgkin lymphoma.
Makita S; Maruyama D; Maeshima AM; Taniguchi H; Yuda S; Toyoda K; Yamauchi N; Fukuhara S; Munakata W; Kobayashi Y; Kurihara H; Izutsu K; Tobinai K
Asia Pac J Clin Oncol; 2020 Jun; 16(3):108-114. PubMed ID: 31802636
[TBL] [Abstract][Full Text] [Related]
12. Staging and response assessment in lymphomas: the new Lugano classification.
Cheson BD
Chin Clin Oncol; 2015 Mar; 4(1):5. PubMed ID: 25841712
[TBL] [Abstract][Full Text] [Related]
13. [Hybrid imaging in lymphoma].
Mayerhöfer ME; Haug A
Radiologe; 2020 May; 60(5):376-385. PubMed ID: 32296856
[TBL] [Abstract][Full Text] [Related]
14. [Values of Different Evaluation Criteria of Interim
Zhu LT; Cen XN; Ou JP; Qiu ZX; Wang LH; Liu W; Wang WS; Dong YJ; Liang ZY; Wang MJ; Xu WL; Sun YH; Wang Q; Yin Y; Ren HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):431-437. PubMed ID: 28446288
[TBL] [Abstract][Full Text] [Related]
15. Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor assessment.
Winkelmann M; Bücklein VL; Blumenberg V; Rejeski K; Ruzicka M; Unterrainer M; Schmidt C; Dekorsy FJ; Bartenstein P; Ricke J; von Bergwelt-Baildon M; Subklewe M; Kunz WG
Front Oncol; 2022; 12():974029. PubMed ID: 36158658
[TBL] [Abstract][Full Text] [Related]
16. Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients.
Mayerhoefer ME; Karanikas G; Kletter K; Kiesewetter B; Weber M; Rausch I; Pones M; Simonitsch-Klupp I; Müllauer L; Dolak W; Lukas J; Raderer M
Clin Nucl Med; 2016 Nov; 41(11):837-843. PubMed ID: 27648705
[TBL] [Abstract][Full Text] [Related]
17. Multicenter Comparison of Contrast-Enhanced FDG PET/CT and 64-Slice Multi-Detector-Row CT for Initial Staging and Response Evaluation at the End of Treatment in Patients With Lymphoma.
Gómez León N; Delgado-Bolton RC; Del Campo Del Val L; Cabezas B; Arranz R; García M; Cannata J; González Ortega S; Pérez Sáez MÁ; López-Botet B; Rodríguez-Vigil B; Mateo M; Colletti PM; Rubello D; Carreras JL
Clin Nucl Med; 2017 Aug; 42(8):595-602. PubMed ID: 28604477
[TBL] [Abstract][Full Text] [Related]
18. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).
Younes A; Hilden P; Coiffier B; Hagenbeek A; Salles G; Wilson W; Seymour JF; Kelly K; Gribben J; Pfreunschuh M; Morschhauser F; Schoder H; Zelenetz AD; Rademaker J; Advani R; Valente N; Fortpied C; Witzig TE; Sehn LH; Engert A; Fisher RI; Zinzani PL; Federico M; Hutchings M; Bollard C; Trneny M; Elsayed YA; Tobinai K; Abramson JS; Fowler N; Goy A; Smith M; Ansell S; Kuruvilla J; Dreyling M; Thieblemont C; Little RF; Aurer I; Van Oers MHJ; Takeshita K; Gopal A; Rule S; de Vos S; Kloos I; Kaminski MS; Meignan M; Schwartz LH; Leonard JP; Schuster SJ; Seshan VE
Ann Oncol; 2017 Jul; 28(7):1436-1447. PubMed ID: 28379322
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT-Controlled Prospective Study in 64 Patients.
Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Knogler T; Sillaber C; Jaeger U; Simonitsch-Klupp I; Ubl P; Müllauer L; Dolak W; Lukas J; Raderer M
Clin Cancer Res; 2015 Jun; 21(11):2506-13. PubMed ID: 25733598
[TBL] [Abstract][Full Text] [Related]
20. Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma.
McCarten KM; Nadel HR; Shulkin BL; Cho SY
Pediatr Radiol; 2019 Oct; 49(11):1545-1564. PubMed ID: 31620854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
